A novel algorithm to improve specificity in ovarian cancer detection

Arjomandi, Audrey; Delanoy, Michelle; Walker, Roger P.; Binder, Steven R.

doi:10.1016/j.ctarc.2017.11.004

Cited by 3 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These biomarkers maintain sensitivity in the setting of false-negative CA-125 levels, and, unlike CA-125, maintain specificity even when compared to benign ovarian disease. Despite the low detectable rate of p53-AAbs in serum, another group described the combinational use of protein and peptide epitopes as a novel approach to identify AAbs more specific for ovarian cancer screening (65). This method could reduce the number of false-positive samples in the healthy population.…”

Section: Mutant P53 As Screening Biomarker For Eocmentioning

confidence: 99%

TP53 mutations in epithelial ovarian cancer

Zhang

Cao

Nguyen

et al. 2016

Transl. Cancer Res.

View full text Add to dashboard Cite

Genomic sequencing analyses of a variety of human cancers have revealed that massive mutations of cancer-relevant genes are the major alterations in cancerous cells, and their mutation frequencies or rates are highly associated with the development, progression, metastasis, and drug resistance of cancers as well as their clinical outcomes and prognosis. One predominant genetic alternation in human epithelial ovarian cancer (EOC) is the mutation of TP53 that encodes the tumor suppressor p53 protein. This essay will review the most recent progress in understanding the role of TP53 mutations in development, progression, and metastasis of EOC, and discuss the potential of TP53 mutations as diagnostic and prognostic biomarkers as well as therapeutic targets for EOC.

show abstract

Section: Mutant P53 As Screening Biomarker For Eocmentioning

confidence: 99%

TP53 mutations in epithelial ovarian cancer

Zhang

Cao

Nguyen

et al. 2016

Transl. Cancer Res.

View full text Add to dashboard Cite

show abstract

“…Currently, there are many studies conducted aiming at determination of a possible application of anti-p53 autoantibodies in the diagnostics of ovarian cancer. Arjomandi et al [25] presented an innovative algorithm which could increase the specificity and sensitivity of potential tests for early detection of ovarian cancer. For detection, the authors used the protein p53 complex with selected antigenic epitopes.…”

Section: Discussionmentioning

confidence: 99%

The immune complex p53 protein/anti-p53 autoantibodies in the pathogenesis of ovarian serous carcinoma

et al. 2020

View full text Add to dashboard Cite

Objectives: The tests conducted were intended to analyze the concentration of p53 protein and anti-p53 autoantibodies in serum of women with ovarian tumours. Material and methods: The study included patients with diagnosed ovarian cancer: Cystadenoma serosum or Cystadenocarcinoma papillare serosum at IIIc stage (including 10 women who had G1, 14 women who had G2 and 30 women who had G3 staging). Concentrations of parameters were measured by ELISA. Results: The analysis of the obtained results showed statistical significance between the concentration of p53 protein depending on the degree of differentiation of G1 and G3 (p < 0.001) and anti-p53 autoantibodies depending on the degree of differentiation of G1 and G2 (p < 0.05) as well as G2 and G3 (p < 0.01). In addition, the determined p53/anti-p53 autoantibodies ratio was only significant between G1 and G2 (p < 0.05), as was the assessment of the percentage of the tested parameters in the immune complex. Conclusions: Immune system disorders involving the p53 protein and anti-p53 autoantibodies may be one of the immune mechanisms involved in the pathogenesis of ovarian serous cancer.

show abstract

“…It has been observed that both stage I and stage II serous ovarian tumors have p53-AAb. A potentially effective biomarker for screening is the presence of p53-AAbs in a patient’s circulation, which may be a signal for early diagnosis of EOC [ 75 ].…”

Section: Reviewmentioning

confidence: 99%

P53 Gene as a Promising Biomarker and Potential Target for the Early Diagnosis of Reproductive Cancers

Arumugam,

Muninathan

et al. 2024

Cureus

View full text Add to dashboard Cite

One of the crucial aspects of cancer research is diagnosis with specificity and accuracy. Early cancer detection mostly helps make appropriate decisions regarding treatment and metastasis. The well-studied transcription factor tumor suppressor protein p53 is essential for maintaining genetic integrity. p53 is a key tumor suppressor that recognizes the carcinogenic biological pathways and eradicates them by apoptosis. A wide range of carcinomas, especially gynecological such as ovarian, cervical, and endometrial cancers, frequently undergo TP53 gene mutations. This study evaluates the potential of the p53 gene as a biological marker for the diagnosis of reproductive system neoplasms. Immunohistochemistry of p53 is rapid, easy to accomplish, cost-effective, and preferred by pathologists as a surrogate for the analysis of TP53 mutation. Thus, this review lays a groundwork for future efforts to develop techniques using p53 for the early diagnosis of cancer.

show abstract

A novel algorithm to improve specificity in ovarian cancer detection

Cited by 3 publications

References 19 publications

TP53 mutations in epithelial ovarian cancer

TP53 mutations in epithelial ovarian cancer

The immune complex p53 protein/anti-p53 autoantibodies in the pathogenesis of ovarian serous carcinoma

P53 Gene as a Promising Biomarker and Potential Target for the Early Diagnosis of Reproductive Cancers

Contact Info

Product

Resources

About